Solventum achieved 4.3% organic sales growth in Q1 2025, driven by strong performance in MedSurg and Health Information Systems. Despite the increase in revenue, net income and operating income fell sharply year-over-year due to higher costs and margin pressures. Free cash flow turned negative, reflecting investment and operating dynamics post-spin-off.
Revenue reached $2.07 billion, growing 2.6% overall and 4.3% organically.
Net income declined to $137 million from $237 million in Q1 2024.
GAAP EPS was $0.78; adjusted EPS was $1.34.
Free cash flow was negative at -$80 million, down from $340 million last year.
Solventum raised its full-year 2025 organic sales growth guidance by 50 basis points while maintaining adjusted EPS and free cash flow targets.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance